CSIMarket Company Name, Ticker, Industry, else..
 
Compass Therapeutics Inc   (NASDAQ: CMPX)
 
Price: $2.3800 $0.01 0.422%
Day's High: $2.444999933242798 Week Perf: -0.42 %
Day's Low: $ 2.33 30 Day Perf: 24.61 %
Volume (M): 2,541,400 52 Wk High: $ 6.88
Volume (M$): $ 0 52 Wk Avg: $4.00
Open: $2.34 52 Wk Low: $1.61



 Market Capitalization (Millions $) 444
 Shares Outstanding (Millions) 186
 Employees 39
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -68
 Cash Flow (TTM) (Millions $) 14
 Capital Exp. (TTM) (Millions $) 0

Business Description


Compass Therapeutics Inc is a biotechnology company focused on developing targeted antibody therapies to treat cancer. The company combines computational biology, antibody drug discovery, and translational medicine to create differentiated antibody therapeutics. Compass Therapeutics aims to develop multi-specific antibodies that can simultaneously target multiple disease-associated antigens, potentially leading to more effective and safer treatments. The company's goal is to address the limitations of traditional monoclonal antibody therapies by utilizing their unique approach to drug discovery and development.


   Company Address: 80 Guest St., Suite 601 Boston 2135 MA
   Company Phone Number: 500-8099   Stock Exchange / Ticker: NASDAQ CMPX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        1.11% 
BCRX        1.43% 
BIIB        1.07% 
EXEL        8.37% 
GILD        3.65% 
NVAX        10.37% 
• View Complete Report
   



Clinical Study

Compass Therapeutics Charts a Course Scientific Innovation Meets Market Challenges with CTX-10726,

Published Tue, Nov 4 2025 10:07 PM UTC

In the rapidly evolving field of oncology, biopharmaceutical companies are continuously striving to break new ground and deliver innovative therapies to patients confronting cancer. Compass Therapeutics, Inc. (Nasdaq: CMPX) stands at an intriguing intersection of scientific advancement and market dynamics as they recently unveiled promising preclinical data for their novel b...
Management Announcement

Compass Therapeutics Struggles with Financial Losses but Appoints New CFO to Navigate Drug Development Challenges,

Published Wed, Jan 8 2025 1:01 PM UTC

BOSTON, Jan. 08, 2025 — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on the development of antibody-based therapeutics for various oncology-related diseases, has provided a corporate and financial update revealing formidable challenges intertwined with optimistic progress in their drug development pipeline.In their recent an...
Management Changes

Compass Therapeutics Appoints Barry Shin as CFO: Navigating Clinical Innovations Amid Financial Challenges,

Published Tue, Dec 10 2024 1:00 PM UTC

Compass Therapeutics Strengthens Leadership Team Amid Clinical Progress and Financial ChallengesBOSTON, Dec. 10, 2024 — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for oncology, has announced the appointment of Barry Shin as Chief Financial Officer, effective December 9, ...
Clinical Study

Compass Therapeutics Balancing Promising Clinical Developments with Financial Challenges in Oncology Innovations

Published Fri, Nov 8 2024 3:05 PM UTC

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company specializing in oncology, continues to advance its research portfolio despite facing significant financial hurdles. At the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Houston, Texas, from November 6-10, 2024, the company presented promising new findings related to...
Clinical Study

Compass Therapeutics Marks Milestone with Successful Patient Enrollment in Pioneering Biliary Tract Cancer Trial

Published Tue, Aug 6 2024 12:00 PM UTC

Compass Therapeutics Completes Patient Enrollment in COMPANION-002: A Landmark Achievement in Biliary Tract Cancer Research BOSTON, Aug. 6, 2024 In a significant advancement in the realm of oncology, Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company renowned for its focus on antibody-based therapeutics, has successfully completed patient...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 2.38
PEG (TTM) -

Financial Strength Current
Quick Ratio 18.94
Working Capital Ratio 19.04
Leverage Ratio (MRQ) 0.1
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.42 $
Revenues (TTM) -
Cash Flow (TTM) 0.08 $
Cash 1.04 $
Book Value 1 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,748,026
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.